The RNA-binding protein LRPPRC promotes resistance to CDK4/6 inhibition in lung cancer

Kinase inhibitors against Cyclin Dependent Kinase 4 and 6 (CDK4/6i) are promising cancer therapeutic drugs. However, their effects are limited by primary or acquired resistance in virtually all tumor types. Here, we demonstrate that Leucine Rich Pentatricopeptide Repeat Containing (LRPPRC) controls...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Wei, Wang, Wenxi, Liang, Yuxin, Jiang, Ruibin, Qiu, Fensheng, Shao, Xiying, Liu, Yang, Fang, Le, Ni, Maowei, Yu, Chenhuan, Zhao, Yue, Huang, Weijia, Li, Jiong, Donovan, Michael J., Wang, Lina, Ni, Juan, Wang, Dachi, Fu, Ting, Feng, Jianguo, Wang, Xiaojia, Tan, Weihong, Fang, Xiaohong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349134/
https://www.ncbi.nlm.nih.gov/pubmed/37452037
http://dx.doi.org/10.1038/s41467-023-39854-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349134/
https://www.ncbi.nlm.nih.gov/pubmed/37452037
http://dx.doi.org/10.1038/s41467-023-39854-y

Ejemplares similares